Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 11, 2015GlycobiologyOpen Access

Fc glycans of therapeutic antibodies as critical quality attributes

View Full Paper
Ask AI
Bookmark
Share

Authors

DRDietmar ReuschRoche (Switzerland)MTMax L. TejadaAstraZeneca (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Reusch et al. (2015) studied this question.

synapsesocial.com/papers/69daa5ab85037e71b2684625https://doi.org/10.1093/glycob/cwv065
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Presence of Gal‐α1,3Gal epitope on xenogeneic lines: implications for cellular gene therapy based on the encapsulation technology2003 · 8 citations
  2. 2Generation of Arabidopsis thaliana plants with complex N ‐glycans lacking β1,2‐linked xylose and core α1,3‐linked fucose2004 · 327 citations
  3. 3Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities2012 · 127 citations
  4. 4Control of Recombinant Monoclonal Antibody Effector Functions by Fc N‐Glycan Remodeling in Vitro2005 · 394 citations
  5. 5Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation2006 · 1,767 citations